Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Halfbenzinga_article·7 hours agoHROW-2.64%HROWL0.00%
Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injectionsPUBT·1 day ago, 06:01 AMHROW-2.64%HROWM0.00%
Harrow Chief Scientific Officer Amir Shojaei disposes of 11,250 common shares worth $450,000PUBT·Aug 17 at 04:48 PMHROWL0.00%HROW-2.64%
HC Wainwright Issues Pessimistic Outlook for Harrow EarningsMarket Beat·Aug 14 at 07:13 AMHROW-2.64%HROWM0.00%
HC Wainwright Forecasts Harrow's Q4 Earnings (NASDAQ:HROW)Market Beat·Aug 13 at 06:42 AMHROWM0.00%HROW-2.64%
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings MissMarket Beat·Aug 11 at 09:20 AMHROW-2.64%HROWM0.00%
HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipelineQuartr·Aug 10 at 09:05 PMHROWL0.00%HROWM0.00%
Harrow Q2 FY26 net loss widens to $17.27 million; revenue rises 11% to $70.66 millionPUBT·Aug 10 at 03:07 PMHROW-2.64%HROWM0.00%
B. Riley Securities Keeps Their Buy Rating on Harrow Health (HROW)Tip Ranks·Aug 10 at 08:48 AMHROW-2.64%HROWM0.00%
Arista Networks Stock Leads Fast Growth Picks With High Insider OwnershipSimplywall·Aug 6 at 04:31 PMHROWM0.00%ANET+2.67%
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlookbenzinga_article·Aug 6 at 12:56 PMVTRS+2.00%HROWL0.00%
Harrow to buy dry eye nasal spray Tyrvaya from Viatris for up to $100 millionPUBT·Aug 6 at 06:12 AMHROW-2.64%HROWL0.00%
